Company Description
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).
In addition, it is investigating a CD-22 targeted compound’ and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia.
Further, the company’s pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2.
ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
| Country | Switzerland |
| Founded | 2011 |
| IPO Date | May 15, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 265 |
| CEO | Ameet Mallik |
Contact Details
Address: BiopOle, Route de la Corniche 3B Epalinges, 1066 Switzerland | |
| Phone | 41 21 653 02 00 |
| Website | adctherapeutics.com |
Stock Details
| Ticker Symbol | ADCT |
| Exchange | NYSE |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0000061478 |
| CUSIP Number | H0036K147 |
| ISIN Number | CH0499880968 |
| Employer ID | 41-0743912 |
| SIC Code | 3661 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ameet Mallik M.B.A., M.S. | Chief Executive Officer and Director |
| Jose I. Carmona M.B.A. | Chief Financial Officer |
| Dr. Mohamed Zaki M.D., Ph.D. | Chief Medical Officer |
| Lisa Michelle Kallebo | Corporate Controller and Chief Accounting Officer |
| Dr. David S. Ege Ph.D. | Chief Technical Officer |
| Dr. Patrick van Berkel Ph.D. | Chief Scientific Officer |
| Marcy Graham | Investor Relations Officer |
| Peter J. Graham Esq. | Secretary and Chief Legal Officer |
| Kimberly Pope | Senior Vice President and Chief People Officer |
| Kristen Harrington-Smith | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2010 | 15-12G | Securities registration termination |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 10, 2010 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 9, 2010 | SC 14D9/A | Filing |
| Dec 9, 2010 | SC TO-T/A | Filing |
| Dec 9, 2010 | 25-NSE | Filing |
| Dec 9, 2010 | 8-K | Current Report |